Febuxostat PCD Pharma Franchise Company
Cafoli Lifecare offers a Febuxostat PCD pharma franchise built on 3 tablet formulations manufactured at WHO-GMP certified facilities. This gives franchise partners a modern gout and hyperuricaemia line prescribed by rheumatologists, nephrologists and physicians.
What is Febuxostat?
Febuxostat is a potent, non-purine selective inhibitor of xanthine oxidase, the enzyme that produces uric acid. By lowering serum urate it prevents gout flares and the deposition of urate crystals, and unlike allopurinol it can be used without dose reduction in mild-to-moderate renal impairment. Read its profile on MedlinePlus.
Therapeutic Applications
Febuxostat is prescribed for the long-term management of chronic hyperuricaemia in gout to prevent recurrent flares and tophi, and is used where allopurinol is not tolerated or is contraindicated. Prescriptions come mainly from rheumatologists, nephrologists, orthopaedic surgeons and general physicians.
Why Febuxostat is a High-Potential Molecule for Distributors
Gout prevalence is rising with changing diet and lifestyle in India, and urate-lowering therapy is lifelong — patients stay on febuxostat indefinitely, producing steady month-after-month repeat sales. Its usability in renal impairment, where allopurinol dosing is restricted, is steadily shifting prescribers toward it. That switch trend in a growing patient pool makes febuxostat a reliable chronic-care earner.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Febuxostat
- PubChem: Febuxostat
Our formulations of Febuxostat find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: